#ASH20 saw a BC­MA brawl. Who's still stand­ing? And who got knocked out for good?

Can too much suc­cess be a bad thing?

Prob­a­bly not for pa­tients, but for drug com­pa­nies the over­whelm­ing suc­cess of BC­MA-tar­get­ing ther­a­pies is prob­a­bly go­ing to mean that, de­spite pos­i­tive re­sults, some com­pa­nies are go­ing to lose out to oth­ers that put up bet­ter ones.

“ASH pre­sen­ta­tions ap­pear fine but so do all the com­peti­tors,” Baird’s Bri­an Sko­r­ney wrote of Re­gen­eron’s re­sults, sum­ming up a cool, wide­spread en­thu­si­asm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER